Waiting time to surgery and pancreatic cancer survival: A nationwide population-based cohort study.


Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 30 03 2019
revised: 16 05 2019
accepted: 27 05 2019
pubmed: 5 6 2019
medline: 11 6 2020
entrez: 5 6 2019
Statut: ppublish

Résumé

The effect of waiting time to surgery on survival in pancreatic cancer patients is unclear. We examined this association in a nationwide population-based cohort study. A nationwide population-based cohort study of all patients undergoing surgery for pancreatic cancer (resection or a palliative procedure) registered in the Danish Pancreatic Cancer Database from May 2011 to May 2016. We defined waiting time to surgery in two ways: 1) from the date of entry into the National Cancer Pathway to the date of surgery and 2) from the date of the last preoperative computed tomography (CT) or positron emission tomography (PET-CT) scan to the date of surgery. Waiting time was grouped into three groups: <28 days (<4 weeks), 28-55 days (4-8 weeks), and ≥56 days (≥8 weeks). We calculated median survival with associated 95% confidence intervals (CIs) for patients undergoing resection and for patients undergoing a palliative procedure. We included 873 patients. Mean age was 67 years (range: 35-86 years). Resection was performed in 701 patients (80%); the remaining 172 patients (20%) underwent an explorative laparotomy or palliative surgery. 652 patients (75%) had a registration in the National Cancer Pathway (median waiting time: 31 days, and 818 patients (94%) had registration of a preoperative CT or PET-CT scan (median waiting time: 32 days). We saw similar resection rates (∼80%) and median survival (∼22 months) in all thee groups. In this study, waiting time to surgery did not affect survival in patients undergoing surgery for pancreatic cancer.

Identifiants

pubmed: 31160135
pii: S0748-7983(19)30467-6
doi: 10.1016/j.ejso.2019.05.029
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1901-1905

Informations de copyright

Copyright © 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Auteurs

Jakob Kirkegård (J)

Department of Surgery, Section for Hepato-Pancreato-Biliary Surgery, Aarhus University Hospital, Aarhus, Denmark. Electronic address: jakob.kirkegaard@auh.rm.dk.

Frank Viborg Mortensen (FV)

Department of Surgery, Section for Hepato-Pancreato-Biliary Surgery, Aarhus University Hospital, Aarhus, Denmark.

Carsten Palnæs Hansen (CP)

Department of Surgery, Section for Hepato-Pancreato-Biliary Surgery and Transplantation, Rigshospitalet, Copenhagen, Denmark.

Michael Bau Mortensen (MB)

Department of Surgery, Odense University Hospital, Odense, Denmark.

Mogens Sall (M)

Department of Surgery, Aalborg University Hospital, Aalborg, Denmark.

Claus Fristrup (C)

Department of Surgery, Odense University Hospital, Odense, Denmark; Danish Pancreatic Cancer Database, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH